Chen et al. (2020) showed METTL3 and ALKBH5 upregulation in ccRCC tumors and derived a METTL3/METTL14 prognostic score. In DKD, Shi et al. (2017) found urinary m6A levels fall with disease progression, and constructed a glomerular/PBMC model including METTL3 and ALKBH5 to diagnose early DKD (Li, Xu & Li, 2025). Such clinical reports, though still limited, illustrate the bridge between m6A mechanistic work and human disease. Here, METTL3 is linked to diabetic kidney disease.